These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12529295)

  • 1. Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
    McCann SR; Gately K; Conneally E; Lawler M
    Blood; 2003 Feb; 101(3):1200-1. PubMed ID: 12529295
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
    Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
    Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
    Sobrinho-Simões M; Wilczek V; Score J; Cross NC; Apperley JF; Melo JV
    Blood; 2010 Aug; 116(8):1329-35. PubMed ID: 20462961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
    Kantarjian HM; O'Brien S; Cortes JE; Giralt SA; Rios MB; Shan J; Giles FJ; Thomas DA; Faderl S; De Lima M; Garcia-Manero G; Champlin R; Arlinghaus R; Talpaz M
    Blood; 2002 Sep; 100(5):1590-5. PubMed ID: 12176876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
    Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
    Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma.
    Mughal TI; Goldman JM
    Eur J Cancer; 2001 Mar; 37(5):561-8. PubMed ID: 11290430
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
    Olavarria E; Craddock C; Dazzi F; Marin D; Marktel S; Apperley JF; Goldman JM
    Blood; 2002 May; 99(10):3861-2. PubMed ID: 11986250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
    Press RD; Love Z; Tronnes AA; Yang R; Tran T; Mongoue-Tchokote S; Mori M; Mauro MJ; Deininger MW; Druker BJ
    Blood; 2006 Jun; 107(11):4250-6. PubMed ID: 16467199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
    Agis H; Mannhalter C; Sperr WR; Keil F; Kalhs P; Pirc-Danoewinata H; Krauth MT; Haas OA; Geissler K; Lechner K; Valent P
    Leuk Lymphoma; 2004 Jul; 45(7):1453-8. PubMed ID: 15359647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
    Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
    Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Min CK; Kim HJ; Eom KS; Kim DW; Lee JW; Min WS; Kim CC
    Blood; 2005 May; 105(9):3449-57. PubMed ID: 15657178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of advanced stage chronic myeloid leukemia].
    Takahashi N
    Rinsho Ketsueki; 2014 Oct; 55(10):1860-9. PubMed ID: 25297750
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
    Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
    Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
    Saussele S; Lauseker M; Gratwohl A; Beelen DW; Bunjes D; Schwerdtfeger R; Kolb HJ; Ho AD; Falge C; Holler E; Schlimok G; Zander AR; Arnold R; Kanz L; Dengler R; Haferlach C; Schlegelberger B; Pfirrmann M; Müller MC; Schnittger S; Leitner A; Pletsch N; Hochhaus A; Hasford J; Hehlmann R;
    Blood; 2010 Mar; 115(10):1880-5. PubMed ID: 19965667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
    Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
    Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
    Lin F; Drummond M; O'Brien S; Cervantes F; Goldman J; Kaeda J
    Blood; 2003 Aug; 102(3):1143. PubMed ID: 12869491
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
    Lu X; Song X; Ye Y; Liu X; Zhou Y; Zhang L; Wang J; Ying B; Wang L
    Mol Biol Rep; 2011 Jun; 38(5):3101-5. PubMed ID: 20127176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.